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a b s t r a c t
Background: In the era of bundled payments, many hospitals are responsible for costs from admission
through 90 days postdischarge. Although bundled episodes for hip fracture will have a separate target
price for the bundle, little is known about the 90-day resource use burden for this patient population.
Methods: Using Medicare 100% Standard Analytic Files (2010-2014), we identiﬁed patients undergoing
hemiarthroplasty or total hip arthroplasty (THA). Patients were aged 65 and older with admitting
diagnosis of closed hip fracture, no concurrent fractures of the lower limb, and no history of hip surgery
in the prior 12 months baseline. Continuous Medicare-only enrollment was required. Complications,
resource use, and mortality from admission through 90 days following discharge (follow-up) were
summarized.
Results: Four cohorts met selection criteria for analysis: (1) hemiarthroplasty diagnosis-related group
(DRG) 469 (N ¼ 19,634), (2) hemiarthroplasty DRG 470 (N ¼ 77,744), (3) THA DRG 469 (N ¼ 1686), and
(4) THA DRG 470 (N ¼ 9314). All-cause mortality during the study period was 51.6%, 29.5%, 48.1%, and
24.9% with mean 90-day costs of $28,952, $19,243, $29,763, and $18,561, respectively. Most of the
patients waited 1 day from admission to surgery (41%-51%). Incidence of an all-cause complication was
approximately 70% in each DRG 469 cohort and 14%-16% in each DRG 470 cohort.
Conclusion: This study conﬁrms patients with hip fracture are a costly subpopulation. Tailored care
pathways to minimize post-acute care resource use are warranted for these patients.
© 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Hip fracture places a substantial resource burden on the US
healthcare system. Each year more than 250,000 people over the
age of 65 are hospitalized for hip fracture [1], and this number is
projected to increase with the aging of the population. Currently,
the US healthcare system is rapidly shifting away from a fee-for-
service system to quality-based care. This shift is most evident in
the implementation of Medicare's Bundled Payments for Care
Improvement Initiative (BPCI), the Comprehensive Care for
Joint Replacement (CJR) model, and the recently passed surgical
hip/femur fracture treatmentmodel. For hospitals enrolled in CJR or
BPCI, hospitalizations grouped under diagnosis-related group
(DRG) 469 (major joint replacement of the lower extremity
with major complications or comorbidity) or 470 (major joint
replacement of the lower extremity without complications or
comorbidity) “trigger” a bundled payment episode. DRGs are suf-
ﬁciently broad to include hospitalizations for both elective THA and
arthroplasty due to hip fracture [2].
Given this shift in payment policy, there is a need to establish
mean outcomes and costs incurred over the entire episode of
care for patients admitted for hip fracture on a population level.
AlthoughMedicare has stated that a separate target pricewill be set
for hip fracture patients vs those undergoing elective THA, there is a
paucity of information on this high-cost, high-risk patient popu-
lation. This study aims at estimating the total resource use and cost
among Medicare patients admitted for hip fracture from point of
admission through 90 days postdischarge.
Methods
Overview and Data Source
This retrospective database analysis used healthcare claims data
from the Centers for Medicare & Medicaid Services (CMS) 100%
Limited Data Set (LDS) research ﬁles (2010-2014) to identify
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patients undergoing hemiarthroplasty or THA for hip fracture. CMS
LDS ﬁles contain de-identiﬁed beneﬁciary-level health information,
compliant with the Health Insurance Portability and Accountability
Act (HIPAA Privacy Rule).
Patient Selection and Study Time Period
To best evaluate differences in outcomes by procedure
type while accounting for the separate target episode prices for
DRG 469 vs 470, 4 study cohorts were created: (1) hemiarthroplasty
grouped as DRG 469, (2) hemiarthroplasty grouped as DRG 470, (3)
THA grouped as DRG 469, and (4) THA grouped as DRG 470.
Patients were included in this analysis if aged 65 or older,
with Medicare-only insurance coverage, with an admitting
diagnosis of hip fracture and principal procedure of hemi-
arthroplasty or THA. The date of admission with diagnosis of hip
fracture was deﬁned as the index date for analysis; a baseline
period was deﬁned as the 12 months before the index date with
follow-up deﬁned as the discharge date plus 90 days. Patients
were excluded if they had history during the baseline period of
a primary or revision hip arthroplasty procedure, diagnosis of
cancer, concurrent diagnosis of other fractures of the lower
limbs, and/or open femoral neck fractures (to eliminate frac-
tures due to high-velocity trauma), or any form of supplemental
Medicare-Advantage insurance. Continuous Medicare enroll-
ment was required over the 12-month baseline through the
index hospitalization discharge date. In order to account for
“catastrophic cost” patients, which CMS has ruled will not
impact CJR episode target prices [3], patients were excluded
from analysis if their total 90-day cost was 2 standard
deviations or greater above the mean within the study cohort.
Study Measures
This study summarized patient demographics, clinical history
and comorbidities listed during baseline, inpatient complications
and initial length of stay (LOS), days from admission to surgery,
discharge destination, readmissions, mortality, and total costs over
the 90-day episode of care. Days from admission to surgery was
deﬁned as the date on the Medicare claim for an arthroplasty
procedure code, therefore may not be as precise as procedure time
information listed in a full electronic health record. Costs provided
in this dataset refer to the Medicare total claim amount paid.
Follow-up post-acute care costs were summarized conditional
upon a patient staying in a facility of interest (ie, conditional
means). Follow-up costs were summed from the day of discharge
through 90 days for each discharge destination of interest (inpa-
tient rehabilitation facility [IRF], skilled nursing facility [SNF], home
with home health), with costs summed over the entirety of follow-
up (ie, capturing multiple stays if multiple stays occurred). Total
90-day costs included the sum of total index hospitalization
cost, total readmission cost, outpatient visit costs, and post-acute
care costs (IRF, SNF, home health), presented as an unconditional
mean (ie, an average across the entire study cohortdregardless of
speciﬁc post-acute care utilization). Finally, all post-acute care costs
were only calculated for patients who survived through at least 90
days follow-up, in order to accurately capture all costs occurring
during that time period. This methodology provides conservative
estimates of total post-acute care costs as patients who died during
follow-up almost certainly had greater healthcare utilization;
however, the cost information associated with these patients also
had greater potential for missing information. All costs were
inﬂation-adjusted to 2014 USD using the medical care component
of the consumer price index.
Data Analyses
Descriptive analyses were conducted for all study measures
outlined above, including mean, median, and standard deviation
values for continuous measures and proportions for binary
measures. Statistical signiﬁcance testing compared baseline de-
mographic and clinical characteristics between the hemi-
arthroplasty and THA groups, using the chi-square test for
categorical variables (or Fisher exact test for cell counts <10) and
Kruskal-Wallis test for continuous variables.
Cox proportional hazards models were constructed to eval-
uate predictors of a hospital readmission within 90 days, con-
trolling for age group, sex, region, hospital size, fracture type,
DRG grouping, selected comorbid diagnoses, history of long-
term anticoagulation use, presence of an all-cause complica-
tion during the index hospitalization, presence of a transfusion
during the index hospitalization, index hospitalization LOS, days
to surgery from admission, and initial discharge destination.
Additionally, Cox models were performed to evaluate predictors
of mortality during the index hospitalization or over 90 days
follow-up using the same set of covariates. All analyses were
performed using the Instant Health Data Suite (Boston Health
Economics, Inc, Waltham, MA) and SAS software (version 9.2,
SAS Institute, Cary, NC) packages.
Results
Demographics and Clinical Characteristics
Between January 1, 2010, and December 31, 2014, 19,634
patients met eligibility criteria for analysis in the hemiarthroplasty
DRG 469 cohort; 77,744 in the hemiarthroplasty DRG 470 cohort;
1686 in the THA DRG 469 cohort; and 9314 in the THA DRG 470
cohort. Median age ranged from 79 to 85 years and most of the
patients were female (64%-76%; Table 1).
Most of the patients had a diagnosis of “unspeciﬁed” fracture of
the neck of the femur (65% across all cohorts), followed by
transcervical fractures (approximately 30% for all cohorts) and
pertrochanteric fractures (5%; Table 1). Overall, most of the pa-
tients waited 1 day from admission to surgery; however, approxi-
mately one-ﬁfth of patients in the DRG 469 cohorts waited 3 days or
more. Nearly one-third of patients in the DRG 469 cohorts had
preexisting diagnosis of anemia, and a quarter had history of long-
term anticoagulant use (a conservative estimatedas this relies on
the presence of a diagnosis code rather than pharmacy records
which were not available). A large proportion of patients (9%-24%)
had a history of concurrent psychosis diagnosis (alcohol or drug
induced, transient and persistent unclassiﬁed mental disorders,
delusional disorders, other psychoses, and pervasive develop-
mental disorders), followed by anxiety disorder (8%-12%).
Index Hospitalization and Discharge Destination
Median interquartile range (IQR) hospital LOS was 8 (6-11) days
for each DRG 469 cohort, and 5 (5-7) days for each DRG 470
cohort. More than 50% of patients in each DRG 469 cohort
remained in the hospital 8 days or longer, compared to 15% in each
DRG 470 cohort. Incidence of an all-cause complication was
approximately 70% in each DRG 469 cohort and 14%-16% in each
DRG 470 cohort. Incidence of transfusion was signiﬁcantly greater
among each THA cohort compared to the hemiarthroplasty
cohorts (P < .001), ranging from 24.7% to 42.3%. Among the DRG
469 cohorts, mortality during the index hospitalization was
signiﬁcantly higher than the DRG 470 cohorts (17.6% vs 2.4% for
hemiarthroplasty, P < .001; 18.6% vs 2.7% for THA, P < .001).
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Overall, mortality was not different between the hemiarthroplasty
and THA cohorts (P ¼ .142).
Most of the patients were discharged to an SNF following the
index hospitalization (62.5% hemiarthroplasty DRG 469, 63.8%
hemiarthroplasty DRG 470, 56.6% THA DRG 469, and 50.2% THA
DRG 470), followed by IRF (16.5%, 23.1%, 22.9%, and 27.3%, respec-
tively). Among patients initially discharged to an SNF, median LOS
ranged from 22 to 26 days (over the entirety of 90-day follow-up,
Table 1
Patient Demographics and Clinical Characteristics.
Parameter Hemiarthroplasty DRG 469 Hemiarthroplasty DRG 470 P Valuea THA DRG 469 THA DRG 470 P Valueb P Valuec
Sample size (N) 19,634 77,744 1686 9314
Age
Mean ± SD 83.89 ± 7.16 82.94 ± 7.19 <.001 81.27 ± 7.62 78.51 ± 7.69 <.001 <.001
Median 85 84 82 79
Age-group (%) <.001 <.001 <.001
65-74 11.7 14.1 20.7 33.4
75-84 37.2 40.2 42.1 41.8
85-89 28.3 27.3 22.9 16.8
90 22.7 18.4 14.4 7.9
Female (%) 64.5 75.6 <.001 63.8 74.1 <.001 .030
Census division (%) <.001 .005 <.001
South Atlantic 20.3 21.7 20.5 24.6
East North Central 17.3 16.0 15.5 14.6
Middle Atlantic 11.4 12.3 13.8 11.9
West South Central 11.0 12.2 12.5 12.4
Paciﬁc 10.3 9.5 9.8 9.1
West North Central 10.1 8.8 10.3 8.5
East South Central 8.8 8.8 8.6 8.6
Mountain 5.5 5.9 5.2 6.1
New England 5.3 4.9 3.8 4.1
Hospital size (# of beds, %)
Small (200) 35.1 38.3 <.001 35.8 34.1 .198 <.001
Medium (201-400) 39.3 37.6 <.001 35.1 35.9 .536 <.001
Large (>400) 25.6 24.1 <.001 29.2 30.0 .511 <.001
Fracture type (%)
Transcervical 29.9 30.1 .639 28.9 29.6 .597 .251
Pertrochanteric 3.7 3.1 .000 6.9 5.0 .003 <.001
Unspeciﬁed part of neck of femur 66.9 67.0 .759 64.7 65.9 .357 .004
Time from admission to surgery date (%) <.001 <.001 <.001
Day of admission 19.6 26.0 18.2 25.8
1 d 43.6 51.4 41.3 48.1
2 d 19.3 15.7 19.7 17.6
3 d 17.6 7.0 20.7 8.5
Comorbid diagnoses in baseline (%)
Rheumatologic disease
Rheumatoid arthritis 2.5 2.4 .697 4.3 3.1 .014 <.001
Osteoarthrosis 18.8 17.4 <.001 20.5 18.3 .035 .030
Bone disorders
Osteoporosis 15.8 15.8 .788 17.1 15.3 .057 .501
Osteopenia or osteomalacia 4.1 4.2 .568 4.3 5.2 .133 <.001
Hematologic
Anemia 29.2 19.0 <.001 28.5 15.3 <.001 <.001
Long-term anticoagulant use 22.7 16.3 <.001 22.6 13.6 <.001 <.001
Weightd (%)
Obese 2.4 1.3 <.001 3.9 1.9 <.001 <.001
Overweight 0.5 0.4 .182 0.7 0.4 .329 1.000
Underweight 1.8 0.9 <.001 1.0 0.4 .003 <.001
Cognitive status (%)
Alcohol or substance abuse 5.6 4.0 <.001 6.3 4.1 <.001 .608
Anxiety disorder 11.8 9.4 <.001 11.0 7.7 <.001 <.001
Psychoses 24.3 19.4 <.001 14.5 8.5 <.001 <.001
Major depressive disorder 1.5 1.3 .067 1.6 0.9 .014 .009
Dementia 6.8 5.6 <.001 4.6 2.1 <.001 <.001
Charlson score breakout (%) <.001 <.001 <.001
0 46.6 63.2 49.8 71.5
1 14.0 11.6 16.4 12.8
2 14.9 12.8 13.4 8.0
3 24.5 12.4 20.3 7.6
THA, total hip arthroplasty; DRG, diagnosis-related group; SD, standard deviation; ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation;
BMI, body mass index.
a Comparison of hemiarthroplasty DRG 469 to hemiarthroplasty DRG 470.
b Comparison of THA DRG 469 to THA DRG 470.
c Comparison of hemiarthroplasty overall (both DRGs combined) to THA overall (both DRGs combined).
d Indicated by an ICD-9-CM diagnosis for overweight/obesity/underweight. No BMI-speciﬁc information was available in this dataset.
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including any repeat admissions). Among patients discharged to an
IRF, median LOS was 11-25 days.
Readmissions and Overall Mortality
Incidence of readmission within 90 days of discharge was
26% for each DRG 469 cohort (hemiarthroplasty and THA), 18%
among hemiarthroplasty DRG 470, and 14% among THA DRG 470
(Table 2), with readmission signiﬁcantly more common among all
hemiarthroplasty procedures (regardless of DRG grouping) vs THA
(P < .001). Across all cohorts, median time to readmission ranged
from 23 to 29 days with median LOS of 5-6 days. Mortality during
readmissions ranged from 11.1% to 16.2%, with mortality signiﬁ-
cantly greater in the hemiarthroplasty cohorts compared to THA
(P ¼ .042). The most common diagnoses for readmission were
infection (10.7%-17.7% dependent on the cohort), dislocation of the
joint (4.5%-8.4%), and wound disruption (1.6%-1.9%). Overall,
mortality between index admission and 90 days postdischarge
was 51.6% for hemiarthroplasty DRG 469, 29.5% for hemi-
arthroplasty DRG 470, 48.1% for THA DRG 469, and 24.9% for THA
DRG 470. Median time to mortality was 21, 38, 19, and 39 days,
respectively.
Total 90-Day Costs
The median cost of the index hospitalizationwas approximately
$21,000 for each DRG 469 cohort and $13,000 for each DRG 470
cohort (Table 3). Among patients with a readmission, median
readmission cost was approximately $9000 for DRG 469 and $7500
for DRG 470. Median cost for IRF stays ranged from $13,707-
$17,299; for SNF stays, median cost ranged from $9269 to $12,671.
Overall, regardless of speciﬁc post-acute care utilization or read-
missions, the median total 90-day cost among patients surviving 90
days was $27,201 for hemiarthroplasty DRG 469; $17,143 for DRG
470; $29,900 for THA DRG 469; and $17,408 for THA DRG 470.
When median total 90-day costs (among patients surviving 90
days) were compared by census region, costs ranged from
approximately $15,400 in the West North Central census region
(IA, KS, MN, MO, NE, ND, SD) to approximately $20,000 in New
England (CT, ME, MA, NH, RI, VT) for each of the DRG 470 cohorts.
For the hemiarthroplasty DRG 469 cohort, total 90-day costs ranged
from $24,408 in the East South Central (AL, KY, MS, TN) region to
$30,200 in the Paciﬁc; and for THA DRG 469 costs ranged from
$24,698 in East North Central (Il, IN, MI, OH and WI) to $33,772 in
New England.
Multivariate Analyses
Cox proportional hazards models were used to evaluate factors
associated with increased risk of readmission within 90 days. At
least 3 of the 4 study cohorts included the following as signiﬁcant
predictors of readmission (all P < .05): age 90 or older (relative to
age 65-74), male gender, residence in the West South Central
(relative to New England), diagnosis of obesity or overweight,
anxiety disorder, psychoses, history of long-term anticoagulant
use, presence of an all-cause complication during the index hos-
pitalization, receipt of a transfusion during index, and initial
discharge to an SNF (compared to home with home health or
under self-care).
Separate Cox proportional hazards models evaluated factors
associated with increased risk of mortality either during the index
visit or over 90 days follow-up (Table 4). The following factors were
signiﬁcant (all P < .05) for each of the 4 study cohorts: age 90 or
older, male gender, diagnosis of psychoses, presence of an all-cause
complication during the index visit, and discharge to a location
other than home, home health, SNF, or IRF. In exploratory gener-
alized linearmodels evaluating index LOS, presence of a transfusion
during the index hospital stay and time from admission to surgery
of 3 days or longer were signiﬁcant predictors of longer LOS in 3 of
the 4 cohorts; however, all other measures predictive of LOS were
not consistently signiﬁcant across study groups.
Discussion
This retrospective analysis of Medicare claims data quantiﬁes







P Valuea THA DRG 469 THA DRG 470 P Valueb P Valuec
Sample size (N) 19,634 77,744 1686.00 9314.00
Any readmission within 90 d (%) 25.7 18.4 <.001 26.3 13.9 <.001 <.001
Time to readmission (d)
Mean ± SD 31.7 ± 24.7 34.9 ± 25.4 <.001 31.0 ± 25.2 35.9 ± 26.0 <.001 .588
Median (IQR) 25.0 (11.0-49.0) 29.0 (13.0-54.0) 23.0 (11.0-47.0) 29.0 (13.0-56.0)
Readmission LOS (d)
Mean ± SD 6.8 ± 4.8 6.3 ± 7.1 <.001 6.6 ± 4.4 6.0 ± 4.3 .002 .006
Median 6.0 (4.0-8.0) 5.0 (4.0-7.0) 5.0 (4.0-8.0) 5.0 (4.0-7.0)
Mortality during readmission (%) 16.2 15.3 .230 15.1 11.1 .138 .042
Readmission diagnoses and procedures (%)
Any infection 17.7 16.1 .007 17.8 10.7 <.001 <.001
Septicemia 14.0 11.4 <.001 13.1 7.3 <.001 <.001
Bacteremia 1.2 0.9 .056 1.6 0.5 .027 .225
Bone infection 0.8 0.6 .437 0.7 0.4 .429 .406
Infection NOS 3.0 4.0 .001 4.3 2.9 .168 .263
Dislocation of prosthetic joint 4.5 4.5 1.000 7.4 8.4 .614 <.001
Wound disruption 1.6 1.6 .748 1.6 1.9 .784 .836
Periprosthetic fracture 0.8 1.2 .009 1.4 2.2 .386 .008
Implant loosening or failure 0.2 0.3 .620 0.7 0.8 1.000 .004
Unspeciﬁed mechanical complication of implant 0.4 0.5 .631 0.5 0.6 1.000 .592
Revision surgery 0.9 1.0 .528 1.8 2.6 .426 <.001
Diagnosis of any infection and revision surgery 0.1 0.1 .409 0.5 0.2 .271 .132
THA, total hip arthroplasty; DRG, diagnosis-related group; SD, standard deviation; IQR, interquartile range; LOS, length of stay; NOS, not otherwise speciﬁed.
a Comparison of hemiarthroplasty DRG 469 to hemiarthroplasty DRG 470.
b Comparison of THA DRG 469 to THA DRG 470.
c Comparison of hemiarthroplasty overall (both DRGs combined) to THA overall (both DRGs combined).
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with either hemiarthroplasty or THA, through the 90-day post-
operative period. This population and time window are of
importance due to recent changes in reimbursement policy via the
shift to bundled payments with either Medicare's mandatory
implementation of the CJR program or the voluntary BPCI program.
As this legislation effectively shifts ﬁnancial responsibility from
Medicare to hospitals, it is critical for care systems and providers to
be able to benchmark their costs against both themselves histori-
cally and other hospitals.
Under the CJR program, patients admitted with a primary
diagnosis of hip fracture who are treated with arthroplasty will
trigger a bundled payment episode [3]. If the total cost of care is
below the target price set for the hospital, a repaymentwill occur at
the end of the reconciliation period (annually for CJR and quarterly
for BPCI); conversely, if costs are greater than the target price, the
hospital will be responsible for repaying Medicare a percentage of
the target price. Given that both hemiarthroplasty and THA fall
under DRG 469 and 470 [2], both procedures conceivably count
toward a bundled payment episode; however, there is no formal
mention of hemiarthroplasty in the CMS ﬁnal ruling [3]. Fractures
treated via nonarthroplasty means (DRGs 480-482) will instead fall
under the recently passed surgical hip/femur fracture treatment
bundle. Whether it is hemiarthroplasty or THA alone that “counts”
as an episode under CJR, hospitals are potentially at risk for
ﬁnancial losses without careful oversight of care optimization and
discharge planning.
Our study found that most of the patients who underwent
hemiarthroplasty or THA were discharged to an SNF or IRF;
median SNF LOS ranged from 22 to 26.5 days and 11-14 days for an
IRF. Furthermore, a large proportion (14%-26%) of patients were
readmitted within 90 days. A somewhat surprising ﬁnding was the
high mortality rate observed from admission through 90 days
postdischarge, which ranged from 25% to 30% for the DRG 470
cohorts and 48%-52% for the DRG 469 cohorts. Unlike elective
arthroplasty procedures where approximately 5% of patients fall
into DRG 469, 15%-20% fell into this DRG for THA and hemi-
arthroplasties for fractures, respectively. This larger percentage of
patients grouped into the higher-severity DRG conﬁrms that
fracture patients are presenting more frequently with severe
comorbidities and complications when compared to their elective
counterparts. Our mortality rates may also appear high compared
to prior estimates as the follow-up in this study extends to 90 days
(rather than the more frequently reported 30-day follow-up).
Additionally, the Medicare dataset used in this study is linked to
Social Security information, thereby providing the most robust
estimate of patient mortality available (compared to provider-only
information). Considering approximately 20% of patients with
fracture grouped into DRG 469 waited 3 or more days before
surgery, which may have been necessary to stabilize complicated
medical issues, a focus on faster preoperative patient optimization
to mitigate the risk of complications and mortality may be
indicated [4,5].
When examining the question of whether to perform a hemi-
arthroplasty or THA, patient age, functional status, comorbidity
burden, and ultimately patient preference must be taken into







P Valuea THA DRG 469 THA DRG 470 P Valueb P Valuec
Total index hospitalization cost
N 18,949 77,021 1613 9176
Mean ± SD $21,245 ± 4239 $13,443 ± 2855 <.001 $21,168 ± 4422 $13,537 ± 3198 <.001 <.001
Median (IQR) $20,826 (18,648-23,624) $12,707 (11,584-14,457) $20,549 (18.580-23,512) $12,661 (11,495-14,534)
Among those readmitted, total readmission cost
N 5005 14,130 441 1272
Mean ± SD $10,473 ± 6408 $9284 ± 5398 <.001 $10,188 ± 6202 $9316 ± 5493 .003 .769
Median (IQR) $8940 (6251-12,394) $7666 (5490-11,642) $8418 (5987-12,002) $7477 (5273-11,739)
Post-acute care costs through 90 dd
Patients with an IRF stay
N 149 514 22 72
Mean ± SD $16,558 ± 5890 $15,865 ± 4892 .037 $14,164 ± 6454 $14,505 ± 4351 .848 .006
Median (IQR) $17,299 (13,146-21,447) $16,065 (13,229-19,644) $16,097 (9338-18,942) $13,707 (10,778-17,952)
Patients with an SNF stay
N 2759 7721 238 640
Mean ± SD $13,140 ± 8373 $12,083 ± 7424 <.001 $13,668 ± 8781 $10,836 ± 6921 <.001 <.001
Median (IQR) $11,934 (6597-18,455) $11,099 (6241-17,139) $12,671 (6623-19,111) $9269 (5407-15,330)
Patients with home health
N 837 4798 115 1214
Mean ± SD $3857 ± 1729 $3681 ± 1582 .001 $3897 ± 1689 $3342 ± 1257 .001 <.001
Median (IQR) $3692 (2757-4864) $3442 (2694-4575) $3646 (2805-4868) $3191 (2610-3884)
Total outpatient visit costse
N 6732 35,339 742 5153
Mean ± SD $896 ± 1395 $583 ± 867 <.001 $928 ± 1434 $608 ± 794 .008 <.001
Median (IQR) $315 (89-978) $249 (80-725) $344 (108-995) $309 (97-836)
Total 90-d costf
N 5614 18,880 411 1286
Mean ± SD $31,121 ± 12,583 $20,483 ± 9499 <.001 $33,401 ± 13,329 $20,640 ± 9302 <.001 <.001
Median (IQR) $27,201 (21,668-38,236) $17,143 (13,625-24,101) $29,900 (23,068-43,321) $17,408 (14,033-24,167)
THA, total hip arthroplasty; DRG, diagnosis-related group; SD, standard deviation; IQR, interquartile range; IRF, inpatient rehabilitation facility; SNF, skilled nursing facility.
a Comparison of hemiarthroplasty DRG 469 to hemiarthroplasty DRG 470.
b Comparison of THA DRG 469 to THA DRG 470.
c Comparison of hemiarthroplasty overall (both DRGs combined) to THA overall (both DRGs combined).
d Post-acute care costs were summed from the day of discharge through 90 days for the facility of interest; conditional upon a patient visit at the facility of interest during
follow-up.
e Outpatient visits included the following locations: emergency department, clinic, ofﬁce, outpatient hospital, outpatient rehab, other outpatient.
f Total 90-day cost is summed for the entire study cohort, regardless of speciﬁc post-acute care utilization (unconditional mean). Total cost is the sum of the index hos-
pitalization, readmission, IRF, SNF, home health, and outpatient visit costs. This cost is calculated only among patients surviving 90 days of follow-up.
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factor in determining total hospitalization cost; however, Medicare
reimbursement is the same (only varying dependent upon DRG
classiﬁcation) [6]. This raises the question of which technique is
“better” for the patient, for which there is no consensus. In a
Cochrane meta-analysis, Parker and Gurusamy [7] concluded that
there is “insufﬁcient evidence” to determine whether hemi-
arthroplasty or THA is the optimal treatment for acute hip fracture.
In another large, retrospective analysis of 2437 patients who
underwent THA vs 38,328 patients with hemiarthroplasty, authors
found no signiﬁcant difference in 90-day complications (including
mortality or readmission for infection, dislocation, revisions, or
thromboembolic disease; odds ratio ¼ 0.89; 95% CI, 0.79-1.02) [8].
By comparison, our study found slightly greater risk of all-cause
complications during the index hospitalization among patients
treated with hemiarthroplasty vs THA (P < .001), and greater risk of
readmission and mortality (both P < .001) within 90 days. These
ﬁndings suggest that in clinical practice, patients with a hemi-
arthroplasty procedure were more comorbid upon presentation
relative to patients with a THA, thereby predisposed to the surgeon
choosing a hemiarthroplasty. This procedural selection is
supported by our Charlson score calculations (an objective proxy
for patient comorbidity status), with 20%-25% of hemiarthroplasty
patients having a score of 3 or greater relative to 8%-12% of THA
patients.
Conclusions
In summary, patients admittedwithhip fracture are a challenging
subpopulation to manage within a bundled care environment. A
myriad of factors affect the 90-day cost of care and the clinical
outcome, including time from admission to surgery, choice of sur-
gical procedure, patient comorbidity status, postoperative compli-
cations and readmissions, and use of post-acute care facilities. These
factors will have to be closely monitored in a bundled environment,
ultimately with the goal of reducing unnecessary medical resource
use, improving outcomes and survival.
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